immune-mediated-diseases
(2)
Attovia Therapeutics
Attovia Therapeutics is a San Carlos, California clinical-stage biotech developing first-in-class multispecific biologics for immune-mediated diseases. Its proprietary ATTOBODY platform builds small-format, biparatopic nanobody medicines with ultra-high (picomolar) affinity, tunable half-life and fast tissue penetration - engineered to hit multiple disease pathways at once. Lead programs ATTO-1310 (anti-IL-31) and ATTO-3712 (IL-13 x IL-31 bispecific) target chronic pruritus and atopic dermatitis. Founded in 2023 out of an Alamar Biosciences and Frazier Life Sciences incubation, the company has raised roughly $255M across Series A through C.
Mirador Therapeutics
Mirador Therapeutics is a San Diego precision-medicine company building first- and best-in-class therapies for immune-mediated inflammatory and fibrotic diseases. Its Mirador360 engine fuses human genetics, multi-modal patient data, AI and advanced analytics to find novel targets, design combination therapies and identify the patients most likely to respond. Founded in 2024 by the former Prometheus Biosciences leadership team, Mirador launched with more than $400 million and has since raised over $650 million total.